Skip to main content
News

Human Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders – MarketWatch

By May 17, 2012No Comments
human-genome-sciences

human-genome-sciences

Human Genome Sciences, Inc.oday announced that its Board of Directors, after careful review and consideration with the assistance of the Company’s management and financial and legal advisors, has unanimously determined that the unsolicited tender offer from GlaxoSmithKline (“GSK”) to acquire all outstanding common shares of HGS for $13.00 per share in cash (the “Offer”) is inadequate, undervalues the Company and is not in the best interests of HGS and its stockholders.

Accordingly, the Board recommends that stockholders reject GSK’s tender offer and not tender any of their shares to GSK. The basis for the Board’s decision is set forth in the Schedule 14D-9 being filed by HGS today with the Securities and Exchange Commission (“SEC”), which will also be mailed shortly to stockholders.

{iframe}http://www.marketwatch.com/story/human-genome-sciences-board-of-directors-unanimously-determines-glaxosmithkline-unsolicited-tender-offer-is-inadequate-and-not-in-the-best-interests-of-stockholders-2012-05-17{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.